S&P Global and CME Group to sell OSTTRA to KKR for $3.1 billion
- Editor
- Apr 14
- 2 min read
Whats Happening:
S&P Global and CME Group have signed a definitive agreement to sell OSTTRA, a leading provider of post-trade solutions for the global OTC market, to investment funds managed by KKR. The deal values OSTTRA at $3.1 billion in total enterprise value, which will be split equally between S&P Global and CME Group as part of their 50/50 joint venture.
Key Moves:
S&P Global and CME Group to sell OSTTRA to KKR for $3.1 billion
OSTTRA management team to continue leading the company
KKR to support OSTTRA's growth with increased investments in technology and innovation
By The Numbers:
OSTTRA valued at $3.1 billion in total enterprise value
OSTTRA processes over 80 million trades monthly
OSTTRA has nearly 1,500 employees
Key Quotes:
"We are incredibly grateful for our partnership with CME Group and S&P Global over the past several years and delighted to have KKR's backing as we embark on this exciting new chapter for OSTTRA," said Guy Rowcliffe and John Stewart, co-CEOs of OSTTRA.
"We have long admired OSTTRA for its mission-critical solutions, deep customer relationships, and strong market position, which we believe provide a great foundation for future growth," said Webster Chua, Partner at KKR.
"OSTTRA has generated significant growth over the past several years, and we are pleased with the role our joint venture played in driving the company forward," said CME Group Chairman and Chief Executive Officer Terry Duffy.
Bottom Line:
The sale of OSTTRA to KKR represents a significant transaction in the post-trade solutions market. With KKR's backing, OSTTRA is poised for further growth and innovation in its critical market infrastructure role. This deal aligns with S&P Global and CME Group's strategic objectives while positioning OSTTRA for future success under new ownership.